Market analysis report tracks pipeline drug development for rheumatoid arthritis
A new industry report details the development status of over 80 rheumatoid arthritis drugs across 75 pharmaceutical companies as of 2025.
ResearchAndMarkets.com has released an assessment of the 2025 pipeline landscape for rheumatoid arthritis (RA) treatments. The report tracks the progress of more than 80 pipeline drugs, evaluating data across 75 pharmaceutical companies. It categorizes products based on their stage of clinical and non-clinical development, molecule type, and route of administration.
RA remains a significant global health concern, affecting approximately 0.24% of the population. While therapeutic options have expanded over the last three decades—shifting the clinical goal toward disease remission and the preservation of joint function—there is currently no cure. Treatment strategies often focus on early intervention with disease-modifying antirheumatic drugs (DMARDs) to prevent permanent joint damage.
The findings provide a comprehensive overview of the industry's investment into RA, including an assessment of inactive projects. By analyzing the current R&D focus, the report serves to highlight the competitive landscape and technological trends driving the development of future immunology therapies.